TABLE 2.

Outcome data among studied COVID‐19 patients treated with tocilizumab versus the standard of care

Parameters	TCZ (n = 51)	Standard of care (n = 78)	p‐value
Length of ICU stay (days)	18.0 (12 – 22)	21 (14 – 28)	0.026*
In‐hospital 28‐day mortality	11 (21.6%)	33 (42.3%)	0.015*
28‐day clinical improvement	28 (54.9%)	9 (11.5%)	0.000*
Need for mechanical ventilation (by day 14)	10 (19.6%)	46 (59.0%)	0.000*
28‐day secondary infections	10 (19.6%)	16 (20.5%)	0.900

Numerical variables – median (interquartile range). Categorical variables – frequency (%).

Abbreviations: ICU, intensive care unit; TCZ, tocilizumab.

^*Statistically significant test (p < 0.05).